Researchers develop a screen for identifying new anticancer drug targets

Apr 05, 2011

Tumor suppressor genes normally control the growth of cells, but cancer can spring up when these genes are silenced by certain chemical reactions that modify chromosomes. Among the most common culprits responsible for inactivating these genes are histone deacetylases, a class of enzymes that remove acetyl groups from DNA-scaffolding proteins, and DNA methyltransferases, a family of enzymes that add methyl groups to DNA.

Drugs that counteract these enzymes, and thus reactivate tumor suppressor genes, are promising cancer therapies. For example, histone deacetylase inhibitors have been approved for the treatment of a type of T cell lymphoma, and are being tested in clinical trials for the treatment of a wide range of cancers. Similarly, DNA methyltransferase inhibitors have been approved to treat a certain kind of leukemia, and are undergoing clinical studies for the treatment of other cancers. But these medications can have serious side effects. Now, Fox Chase Cancer Center postdoctoral associate Andrey Poleshko, PhD, along with Research Professor Richard A. Katz, PhD, and their colleagues have developed a screen to identify proteins that work in conjunction with these enzymes to repress gene expression. They will present their results at the AACR 102nd Annual Meeting 2011 on Tuesday, April 5.

Finding additional proteins that inactivate tumor suppressor genes, and understanding how they work, could lead to the broadening of this class of therapies beyond the two enzyme families, Poleshko said. "If we can find a way to block the action of such proteins, it may be possible to reactivate aberrantly silenced and restore controlled growth in certain ," he noted. Such an approach would avoid interfering directly with the vital chromosome-modifying enzymes.

The researchers genetically programmed human cells to glow fluorescent green upon reactivation of the silent genes they harbor. By shutting down the activity of genes one by one and observing whether cells turned green, they were able to identify factors that help to suppress gene expression.

The method was efficient enough to permit screening of the entire genome, including 21,122 genes, and revealed 128 factors that are involved in regulating .

Explore further: Survival differences seen for advanced-stage laryngeal cancer

add to favorites email to friend print save as pdf

Related Stories

Researchers find gene they believe is key to kidney cancer

May 20, 2010

Researchers at Mayo Clinic's campus in Florida have discovered a key gene that, when turned off, promotes the development of common kidney cancer. Their findings suggest that a combination of agents now being tested in other ...

Newly found enzymes may play early role in cancer

Dec 24, 2008

Researchers have discovered two enzymes that, when combined, could be involved in the earliest stages of cancer. Manipulating these enzymes genetically might lead to targeted therapies aimed at slowing or preventing the onset ...

New suppressor of common liver cancer

Dec 15, 2009

Tumor suppressor genes make proteins that help control cell growth. Mutations in these genes that generate nonfunctional proteins can contribute to tumor development and progression. One of the most well-known tumor suppressor ...

New melanoma tumor suppressor gene uncovered

Mar 29, 2009

National Institutes of Health (NIH) researchers have identified a gene that suppresses tumor growth in melanoma, the deadliest form of skin cancer. The finding is reported today in the journal Nature Genetics as part of a s ...

Ovarian cancer advances when genes are silenced

Dec 13, 2010

There are many mechanisms that alter the activity of genes – direct changes to the DNA code like mutations and deletions, or changes that control when genes are switched on and off, called epigenetic means. Tumor-suppressor ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

Nov 27, 2014

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

Hospital volume not linked to costs of cancer surgery

Nov 26, 2014

(HealthDay)—Hospital surgical volume does not appear to correlate with Medicare payments for cancer surgery, according to research published online Nov. 24 in the Journal of Clinical Oncology.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.